UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 15
 
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
 
 
 
 
Commission File Number
  
000-00935
 
MEDITE Cancer Diagnostics, Inc.
(Exact name of registrant as specified in its charter)
 
10524 Moss Park Rd. Ste-204-357
Orlando, FL 32832
Telephone: (407) 996-9630
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
 
Common Stock, par value $0.001 per share
(Title of each class of securities covered by this Form)
 
No ne
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
 
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 
 
Rule 12g-4(a)(1)
 
Rule 12g-4(a)(2)
 
Rule 12h-3(b)(1)(i)
 
Rule 12h-3(b)(1)(ii)
 
Rule 15d-6
 
Rule 15d-22(b)
 
 
  Approximate number of holders of record as of the certification or notice date: 372


 
 

 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this notice to be signed on its behalf by the undersigned hereunto duly authorized person.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MEDITE Cancer Diagnostics, Inc.
 
 
 
 
 
Date:
 
March 22, 2019
 
 
 
By:
 
/s/ Elmar A. Dave
 
 
 
 
 
 
 
 
Name:
 
Elmar A. Dave
 
 
 
 
 
 
 
 
Title:
 
Chief Executive Officer and President
 
 
 
Medite Cancer Diagnostics (CE) (USOTC:MDIT)
過去 株価チャート
から 11 2024 まで 12 2024 Medite Cancer Diagnostics (CE)のチャートをもっと見るにはこちらをクリック
Medite Cancer Diagnostics (CE) (USOTC:MDIT)
過去 株価チャート
から 12 2023 まで 12 2024 Medite Cancer Diagnostics (CE)のチャートをもっと見るにはこちらをクリック